• Medicare beneficiary access to treatments for Alzheimers disease, including Medicare Part B access issues, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. No: 117-169), including Subtitle B - Prescription Drug Pricing Reform, Part 1 - Lowering Prices through Drug Price Negotiations; and Sections 11402 and 11403 regarding Medicare Part B payment policies for certain biologicals; and provisions regarding application of Maximum Fair Prices and Conforming Amendments [Section 11001, re: Providing for Lower Prices; Subsection (b)] to modify Medicare Part B reimbursement for selected drugs.
• Patient access to treatments for Alzheimers disease, and 340B Drug Pricing Program related issues.

Duration: May 1, 2020 to December 30, 2022

General Issues: Medicare/Medicaid, Health Issues

Spending: about $530,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2020: U.S. Senate, House of Representatives